期刊文献+

小鼠慢性炎症性肠病模型的创建与评价 被引量:1

Establishment and evaluation of models of chronic inflammatory bowel disease in mice
下载PDF
导出
摘要 目的构建小鼠慢性炎症性肠病(IBD)模型,为干细胞治疗研究提供实验模型。方法40只SPF雄性C57BL/6小鼠随机分为Ⅰ~Ⅳ组:Ⅰ组为空白对照组;Ⅱ组持续饲饮硫酸葡聚糖钠(DSS)5d,间隔5d依次循环;Ⅲ组持续饲饮DSS4d,间隔3d,依次循环;Ⅳ组持续饲饮DSS不间隔。监测各组的精神状态、体重、粪便等,于造模后第4、7、28d,各组随机处死3只小鼠,取结肠组织进行病理学观察和免疫组化分析。结果于造模28d,Ⅱ组病死率为100%;Ⅲ组病死率低于20%,病理组织学变化符合IBD临床特点,组织轮廓模糊,黏膜层腺体缺失,结缔组织增生,伴有淋巴细胞浸润;Ⅳ组体重迅速下降,至第9d全部死亡。结论持续给DSS4d,间隔3d依次循环,可制备符合IBD要求的小鼠模型。 Objective To establish the model of inflammatory bowel disease(IBD)in mice and provide test subjects for stem cell therapy research.Methods A total of 40 specific pathogen-free(SPF)male C57BL/6 mice were randomly divided into four groups.Group I was blank control group,groupⅡwas continuously fed with dextran sulfate sodium(DSS)for five days,followed by a 5 d interval for several cycles,groupⅢwas continuously fed with DSS for four days,followed by a 3 d interval for several cycles,and group IV was continuously fed with DSS without interval.The mental state,weight,stool and other situations were monitored for each group.In this study,three random mice from each group were sacrificed respectively four,seven,and 28 days after the establishment of model.Then the colon tissues were taken for pathological observation and immunohistochemical analysis.Results The mortality of groupⅡwas 100%at 28 days after the establishment of model,and that of groupⅢwas lower than 20%.The histopathological changes of groupⅢwere consistent with the clinical characteristics of IBD,including vague tissue contour,gland loss in the mucosal layer,connective tissue hyperplasia,and lymphocyte infiltration.The weight of the mice in group IV dropped rapidly and all mice in this group died on the ninth day.Conclusion The model of mice which meets the requirements of IBD can be established through continuously administration of DDS for four days,followed by a 3 d interval for several cycles.
作者 李青青 郭德镔 郑学忠 鄢东海 阚晓丽 林庆铿 李自安 陈裕浩 潘兴华 Li Qingqing;Guo Debin;Zheng Xuezhong;Yan Donghai;Kan Xiaoli;Lin Qingkeng;Li Zian;Chen Yuhao;Pan Xinghua(Cell Biological Therapy Center of Hospital 920,Joint Logistic Support Force of PLA,National & Local Joint Engineering Laboratory for Stem Cell and Immune Cell Bio-medical Technology,Stem Cell Engineering Laboratory of Yunnan Province,and Clinical College,Kunming General Hospital of Kunming Medical University,Kunming,Yunnan,650032,China)
机构地区 解放军
出处 《西南国防医药》 CAS 2019年第7期725-727,共3页 Medical Journal of National Defending Forces in Southwest China
基金 云南省科技计划重大专项(2018ZF007) 云南省科技计划面上项目(2017FB042)
关键词 炎症性肠病 硫酸葡聚糖钠 小鼠 模型 制备 inflammatory bowel disease dextran sulfate sodium mice model establishment
  • 相关文献

参考文献1

二级参考文献15

  • 1Swan NC, Geoghegan JG, O'Donoghue DP, et al. Fulminant colitis in inflammatory bowel disease: detailed pathologic and clinical analysis [J]. Dis Colon Rectum, 1998, 41 (12): 1511-1515.
  • 2Bryant RV, Winer S, Travis SP, et al. Systemic review: Histological remission in inflammatory bowel disease. Is ' complete' remission the new treatment paradigm? An IOIBD initiative [J]. J Crohns Colitis, 2014, 8(12): 1582-1597.
  • 3Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis[J]. Gut. 2000, 47(3): 404-409.
  • 4Geboes K. Pathology of inflammatory bowel diseases (IBD): variability with time and treatment [J]. Colorectal Dis, 2001, 3 (1): 2-12.
  • 5Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study[J]. Saudi J Gastroenterol, 2011, 17(3):194-198.
  • 6Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study[J]. Gastroenterology Oct,. 2007, 133 (4): 1099- l 105.
  • 7Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing[J]. AmJ Gastroenterol, 2012, 107(11): 1684-1692.
  • 8Travis SP, Higgins PD, Orchard T, et al. Review article: defining remission in ulcerative colitis[J]. Aliment Pharmacol Ther, 2011, 34(2):113-124.
  • 9Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review[J]. Gut, 2012, 61 (11):1619-1635.
  • 10D' Haens GR, Fedorak R, Lemann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn' s disease [J]. Inflamm Bowel Dis, 2009, 15 (10): 1599-1604.

共引文献6

同被引文献14

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部